Statement of Beneficial Ownership (sc 13d)
February 12 2020 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF
1934
(Amendment No.)*
ShockWave
Medical, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
82489T 104
(CUSIP Number)
Armance Bordes
Sofinnova Partners
7-11 boulevard Hausmann
75009 Paris
France
+33 1 76 23 4109
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
December 31, 2019
(Date of Event Which Requires Filing of
this Statement)
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because
of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨
Note: Schedules filed in paper format
shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom
copies are to be sent.
* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
|
CUSIP No. 82489T 104
|
Page 2 of 14
|
|
1.
|
Name
of Reporting Persons
Sofinnova Capital VII FCPR (“SC VII”)
EIN: 98-1028040
|
|
2.
|
Check
the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x
|
|
3.
|
SEC USE ONLY
|
|
4.
|
Source
of Funds (see instructions)
WC
|
|
5.
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
¨
|
|
6.
|
Citizenship
or Place of Organization
France
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7.
|
Sole Voting Power
3,394,206 shares of common stock, except that Sofinnova Partners SAS (“SP SAS”), a French corporation and the management company of SC VII, may be deemed to have sole power to dispose of these shares, and Denis Lucquin (“Lucquin”), Antoine Papiernik (“Papiernik”), Monique Saulnier (“Saulnier”), Graziano Seghezzi (“Seghezzi”) and Henrijette Richter (“Richter”), the managing partners of SP SAS, may be deemed to have shared power to dispose of such shares.
|
|
8.
|
Shared Voting Power
See row 7.
|
|
9.
|
Sole Dispositive Power
3,394,206 shares of common stock, except that SP SAS, a French corporation and the management company of SC VII, may be deemed to have sole power to dispose of these shares, and Lucquin, Papiernik, Saulnier, Seghezzi and Richter, the managing partners of SP SAS, may be deemed to have shared power to dispose of such shares.
|
|
10.
|
Shared Dispositive Power
See row 9.
|
|
11.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
3,394,206
|
|
12.
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)
|
¨
|
|
13.
|
Percent
of Class Represented by Amount in Row 11
12.0%(1)
|
|
14.
|
Type of Reporting Person (see instructions)
00
|
|
(1) The percentage is calculated based upon 28,300,080 shares of common stock outstanding, as reported on the Issuer’s Form 10-Q for the quarterly period ended September 30, 2019 filed with the Commission on November 8, 2019 (the “10-Q”).
|
|
CUSIP No. 82489T 104
|
Page 3 of 14
|
|
1.
|
Name of Reporting Persons
Sofinnova Partners SAS (“SP SAS”)
|
|
2.
|
Check the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x
|
|
3.
|
SEC USE ONLY
|
|
4.
|
Source of Funds (see instructions)
00
|
|
5.
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
¨
|
|
6.
|
Citizenship or Place of Organization
France
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7.
|
Sole Voting Power
3,394,206 shares of common stock, all of which are owned directly by of SC VII. SP SAS, the management
company of SC VII, may be deemed to have sole voting power, and Lucquin, Papiernik, Saulnier, Seghezzi and Richter, the managing
partners of SP SAS, may be deemed to have shared power to vote these shares.
|
|
8.
|
Shared Voting Power
See row 7.
|
|
9.
|
Sole Dispositive Power
3,394,206 shares of common stock, all of which are owned
directly by of SC VII. SP SAS, the management company of SC VII, may be deemed to have sole voting power, and Lucquin, Papiernik,
Saulnier, Seghezzi and Richter, the managing partners of SP SAS, may be deemed to have shared power to vote these shares.
|
|
10.
|
Shared Dispositive Power
See row 9.
|
|
11.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
3,394,206
|
|
12.
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)
|
¨
|
|
13.
|
Percent of
Class Represented by Amount in Row 11
12.0%(1)
|
|
14.
|
Type of Reporting Person (see instructions)
00
|
|
(1) The percentage is calculated based upon 28,300,080 shares of common stock outstanding, as reported on the 10-Q.
|
|
CUSIP No. 82489T 104
|
Page 4 of 14
|
|
1.
|
Name of Reporting Persons
Denis Lucquin (“Lucquin”)
|
|
2.
|
Check the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x
|
|
3.
|
SEC USE ONLY
|
|
4.
|
Source of Funds (see instructions)
00
|
|
5.
|
Check if Disclosure of Legal Proceedings Is Required
Pursuant to Items 2(d) or 2(e)
|
¨
|
|
6.
|
Citizenship or Place of Organization
French Citizen
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7.
|
Sole Voting Power
0
|
|
8.
|
Shared Voting Power
3,394,206 shares of common stock, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII, may be deemed to have sole voting power, and Lucquin, a managing partner of SP SAS, may be deemed to have shared power to vote these shares.
|
|
9.
|
Sole Dispositive Power
0
|
|
10.
|
Shared Dispositive Power
3,394,206 shares of common stock, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII, may be deemed to have sole voting power, and Lucquin, a managing partner of SP SAS, may be deemed to have shared power to vote these shares.
|
|
11.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
3,394,206
|
|
12.
|
Check if the Aggregate Amount in Row (11) Excludes Certain
Shares (see instructions)
|
¨
|
|
13.
|
Percent of Class Represented by Amount in Row 11
12.0%(1)
|
|
14.
|
Type of Reporting Person (see instructions)
IN
|
|
(1) The percentage is calculated based upon 28,300,080 shares of common stock outstanding, as reported on the 10-Q.
|
|
CUSIP No. 82489T 104
|
Page 5 of 14
|
|
1.
|
Name of Reporting Persons
Antoine Papiernik (“Papiernik”)
|
|
2.
|
Check the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x
|
|
3.
|
SEC USE ONLY
|
|
4.
|
Source of Funds (see instructions)
00
|
|
5.
|
Check if Disclosure of Legal Proceedings Is Required
Pursuant to Items 2(d) or 2(e)
|
¨
|
|
6.
|
Citizenship or Place of Organization
French Citizen
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7.
|
Sole Voting Power
0
|
|
8.
|
Shared Voting Power
3,394,206 shares of
common stock, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII, may be deemed to have sole
voting power, and Papiernik, a managing partner of SP SAS, may be deemed to have shared power to vote these shares.
|
|
9.
|
Sole Dispositive Power
0
|
|
10.
|
Shared Dispositive Power
3,394,206 shares
of common stock, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII, may be deemed to have
sole voting power, and Papiernik, a managing partner of SP SAS, may be deemed to have shared power to vote these shares.
|
|
11.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
3,394,206
|
|
12.
|
Check if the Aggregate Amount in Row (11) Excludes Certain
Shares (see instructions)
|
¨
|
|
13.
|
Percent of Class Represented by Amount in Row 11
12.0%(1)
|
|
14.
|
Type of Reporting Person (see instructions)
IN
|
|
(1) The percentage is calculated based upon 28,300,080 shares of common stock outstanding, as reported on the 10-Q.
|
|
CUSIP No. 82489T 104
|
Page 6 of 14
|
|
1.
|
Name of Reporting Persons
Henrijette Richter (“Richter”)
|
|
2.
|
Check the Appropriate Box if a Member of a Group (see
instructions)
(a)
(b)
|
¨
x
|
|
3.
|
SEC USE ONLY
|
|
4.
|
Source of Funds (see instructions)
00
|
|
5.
|
Check if Disclosure of Legal Proceedings Is Required
Pursuant to Items 2(d) or 2(e)
|
¨
|
|
6.
|
Citizenship or Place of Organization
Danish Citizen
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7.
|
Sole Voting Power
0
|
|
8.
|
Shared Voting Power
3,394,206 shares of common stock, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII, may be deemed to have sole voting power, and Richter, a managing partner of SP SAS, may be deemed to have shared power to vote these shares.
|
|
9.
|
Sole Dispositive Power
0
|
|
10.
|
Shared Dispositive Power
3,394,206 shares of common stock, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII, may be deemed to have sole voting power, and Richter, a managing partner of SP SAS, may be deemed to have shared power to vote these shares.
|
|
11.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
3,394,206
|
|
12.
|
Check if the Aggregate Amount in Row (11) Excludes Certain
Shares (see instructions)
|
¨
|
|
13.
|
Percent of Class Represented by Amount in Row 11
12.0%(1)
|
|
14.
|
Type of Reporting Person (see instructions)
IN
|
|
(1) The percentage is calculated based upon 28,300,080 shares of common stock outstanding, as reported on the 10-Q.
|
|
CUSIP No. 82489T 104
|
Page 7 of 14
|
|
1.
|
Name of Reporting Persons
Monique Saulnier (“Saulnier”)
|
|
2.
|
Check the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x
|
|
3.
|
SEC USE ONLY
|
|
4.
|
Source of Funds (see instructions)
00
|
|
5.
|
Check if Disclosure of Legal Proceedings Is Required
Pursuant to Items 2(d) or 2(e)
|
¨
|
|
6.
|
Citizenship or Place of Organization
French Citizen
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7.
|
Sole Voting Power
0
|
|
8.
|
Shared Voting Power
3,394,206 shares of common stock, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII, may be deemed to have sole voting power, and Saulnier, a managing partner of SP SAS, may be deemed to have shared power to vote these shares.
|
|
9.
|
Sole Dispositive Power
0
|
|
10.
|
Shared Dispositive Power
3,394,206 shares of common stock, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII, may be deemed to have sole voting power, and Saulnier, a managing partner of SP SAS, may be deemed to have shared power to vote these shares.
|
|
11.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
3,394,206
|
|
12.
|
Check if the Aggregate Amount in Row (11) Excludes Certain
Shares (see instructions)
|
¨
|
|
13.
|
Percent of Class Represented by Amount in Row 11
12.0%(1)
|
|
14.
|
Type of Reporting Person (see instructions)
IN
|
|
(1) The percentage is calculated based upon 28,300,080 shares of common stock outstanding, as reported on the 10-Q.
|
|
CUSIP No. 82489T 104
|
Page 8 of 14
|
|
1.
|
Name of Reporting Persons
Graziano Seghezzi (“Seghezzi”)
|
|
2.
|
Check the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x
|
|
3.
|
SEC USE ONLY
|
|
4.
|
Source of Funds (see instructions)
00
|
|
5.
|
Check if Disclosure of Legal Proceedings Is Required
Pursuant to Items 2(d) or 2(e)
|
¨
|
|
6.
|
Citizenship or Place of Organization
Italian Citizen
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7.
|
Sole
Voting Power
0
|
|
8.
|
Shared
Voting Power
3,394,206
shares of common stock, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII, may be deemed to
have sole voting power, and Seghezzi, a managing partner of SP SAS, may be deemed to have shared power to vote these shares.
|
|
9.
|
Sole
Dispositive Power
0
|
|
10.
|
Shared
Dispositive Power
3,394,206
shares of common stock, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII, may be deemed to
have sole voting power, and Seghezzi, a managing partner of SP SAS, may be deemed to have shared power to vote these shares.
|
|
11.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
3,394,206
|
|
12.
|
Check if the Aggregate Amount in Row (11) Excludes Certain
Shares (see instructions)
|
¨
|
|
13.
|
Percent of Class Represented by Amount in Row 11
12.0%(1)
|
|
14.
|
Type of Reporting Person (see instructions)
IN
|
|
(1) The percentage is calculated based upon 28,300,080 shares of common stock outstanding, as reported on the 10-Q.
|
|
CUSIP No. 82489T 104
|
Page 9 of 14
|
|
|
Item 1.
|
Security and Issuer
|
|
|
(a)
|
This statement on Schedule 13D relates to the common stock, $0.001 par value per share, of ShockWave
Medical, Inc., a Delaware corporation (the “Issuer”).
|
|
|
(b)
|
5403 Betsy Ross
Drive, Santa Clara, California 95054.
|
|
|
Item 2.
|
Identity and Background
|
|
|
(a)
|
The persons and entities filing this Schedule 13D are Sofinnova Capital VII FCPR (“SC VII”),
Sofinnova Partners SAS, a French corporation (“SP SAS”), and Denis Lucquin (“Lucquin”), Antoine Papiernik
(“Papiernik”), Henrijette Richter (“Richter”), Monique Saulnier (“Saulnier”), and Graziano
Seghezzi (“Seghezzi”), the managing partners of SP SAS (collectively, the “Listed Persons” and together
with SC VII and SP SAS, the “Reporting Persons”).
|
|
|
(b)
|
The address of the principal place of business for each of the Reporting Persons is Sofinnova Partners
SAS, 7-11 boulevard Hausmann, 75009 Paris, France.
|
|
|
(c)
|
The principal occupation of each of the Reporting Persons is the venture capital investment business.
Each of the Listed Persons is employed at the offices of Sofinnova Partners SAS, 7-11 boulevard Hausmann, 75009 Paris, France.
|
|
|
(d)
|
During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding
(excluding traffic violations or similar misdemeanors).
|
|
|
(e)
|
During the last five years, none of the Reporting Persons has been a party to a civil proceeding
of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities
laws or finding any violation with respect to such laws.
|
|
|
(f)
|
SC VII is a French FCPR. SP SAS is a French Corporation. Lucquin, Papiernik and Saulnier are French
citizens. Richter is a Danish citizen. Seghezzi is an Italian citizen.
|
|
|
Item 3.
|
Source and Amount of Funds or Other Consideration.
|
In
July 2013 and January 2015, SC VII purchased a total of 18,579,294 shares of Series A1 preferred stock at $4.72 per share and a
total of 10,004,235 shares of Series A1 preferred stock at $2.54. In May 2015, SC VII purchased a total of 13,527,954 shares of
Series B preferred stock at $8.35 per share. In October 2016, SC VII purchased a total of 7,227,865 shares of Series C preferred
stock for $7.30 per share. In connection with the Issuer’s initial public offering, all of the Series A1 preferred
stock, Series B preferred stock and Series C preferred stock automatically converted into common stock for no additional consideration
in accordance with their respective terms.
No part of the purchase price was borrowed
by any Reporting Person for the purpose of acquiring any securities discussed in this Item 3, and all of the purchase price was
paid through working capital.
|
|
Item 4.
|
Purpose of Transaction.
|
The common stock acquired by SC VII
(described in Item 3 above) was acquired solely for investment purposes. SC VII may,
from time to time, acquire additional shares of common stock or sell all or a portion of the common stock held by SC
VII in the open market or in privately negotiated transactions, or may distribute the
common stock held by SC VII to its unitholders. Any actions SC VII might
undertake will be dependent upon its review of numerous factors, including, among other things, the market prices of the
common stock, general market and economic conditions, ongoing evaluation of the Issuer’s business, financial condition,
operations and prospects, the relative attractiveness of alternative business and investment opportunities,
investors’ need for liquidity, and other future developments.
|
CUSIP No. 82489T 104
|
Page 10 of 14
|
As of the date of this Schedule 13D and
the date of the event to which this Schedule 13D related, and except as provided herein, SC VII has no plans or proposals relating
to or that would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities
of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer
or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d)
any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number
or terms of directors or to fill any existing vacancies on the Board of Directors of the Issuer; (e) any material change in the
present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer’s business or corporate
structure; (g) any changes in the Issuer’s charter, by-laws or instruments corresponding thereto or other actions which may
impede the acquisition of control of the Issuer by any person; (h) a class of securities of the Issuer being delisted from a national
securities exchange or ceasing to be authorized to be quoted in an inter-dealer quotation system of a registered national securities
association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section
12(g)(4) of the Exchange Act; or (j) any action similar to those enumerated above. On December 6, 2019, SCVII entered into a Rule
10b5-1 trading plan (the “10b5-1 Plan”) to sell common stock of the Issuer pursuant to SEC Rule 144.
|
|
Item 5.
|
Interest in Securities of the Issuer.
|
|
|
(a)
|
See Rows 11 and 13 of the cover page for each of the Reporting Persons.
|
|
|
(b)
|
See Rows 7, 8, 9, and 10 for each Reporting Person.
|
|
|
(c)
|
See Item 3 above. SCVII sold common stock of the Issuer on the following dates at the daily average
prices indicated below:
|
|
Date
|
|
Shares
|
|
|
Per Share
Average Price
|
|
|
How Effected
|
|
|
January 14, 2020
|
|
|
58,747
|
|
|
$
|
43.20
|
|
|
|
Open Market
|
|
|
January 15, 2020
|
|
|
58,333
|
|
|
$
|
43.06
|
|
|
|
Open Market
|
|
|
January 16, 2020
|
|
|
61,459
|
|
|
$
|
44.06
|
|
|
|
Open Market
|
|
|
January 17, 2020
|
|
|
97,091
|
|
|
$
|
44.64
|
|
|
|
Open Market
|
|
|
January 21, 2020
|
|
|
169,450
|
|
|
$
|
43.99
|
|
|
|
Open Market
|
|
|
January 22, 2020
|
|
|
54,920
|
|
|
$
|
43.93
|
|
|
|
Open Market
|
|
|
Total:
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
|
(d)
|
Under certain circumstances set forth in the by-laws of SC VII, the equity holders of SC VII and
SP SAS may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of common stock owned
by SC VII.
|
|
|
Item 6.
|
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
|
Papiernik, a managing
partner of SC VII, is a member of the Issuer’s board of directors.
SC VII is party to an Amended and Restated Investors’
Rights Agreement by and among the Issuer, SC VII and other shareholders (the “IRA”). Subject to the terms of the IRA,
holders of shares of common stock having registration rights can demand that the Issuer file a registration statement or request
that their shares be covered by a registration statement that the Issuer is otherwise filing. The IRA is incorporated herein by
reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (File No. 333-229590) filed with the SEC on February
8, 2019.
|
CUSIP No. 82489T 104
|
Page 11 of 14
|
SCVII is a party to a Lock-Up Agreement by and among the Issuer,
the underwriters and certain other parties. SC VII agreed that, subject to specified limited exceptions, for a period of 180 days
from the date of the Prospectus, it would not, without the prior written consent of Morgan Stanley & Co. LLC and Merrill Lynch,
Pierce, Fenner & Smith Incorporated, offer, sell, contract, sell, pledge or otherwise dispose of, including the filing of a
registration statement in respect of, or hedge any of their shares of common stock or any securities convertible into, or exercisable
or exchangeable for common stock; provided, that these restrictions would not apply to common stock purchased in the Offering,
among other exceptions. Morgan Stanley & Co. LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, in their sole
discretion may release any of the securities subject to these lock-up agreements at any time, which, in the case of officers and
directors, shall be with notice.
|
|
Item 7.
|
Material to Be Filed as Exhibits.
|
|
CUSIP No. 82489T 104
|
Page 12 of 14
|
SIGNATURE
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 11, 2020
|
SOFINNOVA CAPITAL VII FCPR
|
|
By:
|
Sofinnova Partners SAS
|
|
|
|
|
By:
|
/s/ Denis Lucquin
|
|
Name:
|
Denis Lucquin
|
|
Title:
|
Managing Partner
|
|
|
|
|
SOFINNOVA PARTNERS SAS
|
|
|
|
|
By:
|
/s/ Denis Lucquin
|
|
Name:
|
Denis Lucquin
|
|
Title:
|
Managing Partner
|
|
|
|
|
By:
|
/s/ Denis Lucquin
|
|
Name:
|
Denis Lucquin
|
|
|
|
|
By:
|
/s/ Antoine Papiernik
|
|
Name:
|
Antoine Papiernik
|
|
|
|
|
By:
|
/s/ Henrijette Richter
|
|
Name:
|
Henrijette Richter
|
|
|
|
|
By:
|
/s/ Monique Saulnier
|
|
Name:
|
Monique Saulnier
|
|
|
|
|
By:
|
/s/ Graziano Seghezzi
|
|
Name:
|
Graziano Seghezzi
|
|
CUSIP No. 82489T 104
|
Page 13 of 14
|
EXHIBITS
|
A.
|
Joint Filing Agreement, dated as of February
11, 2020, by and among Sofinnova Capital VII FCPR, Sofinnova Partners SAS, Denis Lucquin, Antoine Papiernik, Henrijette Richter,
Monique Saulnier and Graziano Seghezzi.
|
|
|
|
|
B.
|
Form of Lock-Up Agreement entered into by and among the Issuer, the underwriters and certain others, filed on November 12, 2019
as Exhibit A to the Underwriting Agreement filed as Exhibit 1.1 to the Issuer’s Registration Statement on Form S-1 filed
with the Commission on November 12, 2019 (File No. 333-234640).
|
|
|
|
|
C.
|
Amended and Restated Investors’ Rights Agreement, between the Issuer and the investors listed on Exhibit A thereto (incorporated
by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (File No. 333-229590) filed with
the SEC on February 8, 2019.
|
|
|
|
|
D.
|
Form of Indemnification Agreement by and between the Issuer and each of its directors and executive officers (incorporated by
reference to Exhibit 10.6 to the Issuer’s Registration Statement on Form S-1 (File No. 333-229590) filed with the SEC on
February 8, 2019.
|
|
CUSIP No. 82489T 104
|
Page 14 of 14
|
EXHIBIT A
JOINT FILING AGREEMENT
In accordance with
Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each
of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock of ShockWave Medical, Inc.
and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes
each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this
joint filing agreement may be signed in counterparts.
In evidence whereof, the undersigned have
caused this Agreement to be executed on their behalf this 11th day of February, 2020.
|
SOFINNOVA CAPITAL VII FCPR
|
|
By:
|
Sofinnova Partners SAS
|
|
|
|
|
By:
|
/s/ Denis Lucquin
|
|
Name:
|
Denis Lucquin
|
|
Title:
|
Managing Partner
|
|
|
|
|
SOFINNOVA PARTNERS SAS
|
|
|
|
|
By:
|
/s/ Denis Lucquin
|
|
Name:
|
Denis Lucquin
|
|
Title:
|
Managing Partner
|
|
|
|
|
By:
|
/s/ Denis Lucquin
|
|
Name:
|
Denis Lucquin
|
|
|
|
|
By:
|
/s/ Antoine Papiernik
|
|
Name:
|
Antoine Papiernik
|
|
|
|
|
By:
|
/s/ Henrijette Richter
|
|
Name:
|
Henrijette Richter
|
|
|
|
|
By:
|
/s/ Monique Saulnier
|
|
Name:
|
Monique Saulnier
|
|
|
|
|
By:
|
/s/ Graziano Seghezzi
|
|
Name:
|
Graziano Seghezzi
|
Shockwave Medical (NASDAQ:SWAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shockwave Medical (NASDAQ:SWAV)
Historical Stock Chart
From Apr 2023 to Apr 2024
